Abstract: The present invention provides compounds of the structural Formula (I), and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Abstract: A first structural frame member (11) has two tabs (15) projecting from one end and may be secured to a second structural frame member (21) having two slots (25) piercing it intermediate its ends by insertion of the tabs through the respective slots N"Z and subsequent deformation of the tabs to prevent their withdrawal from the slots. Each tab tapers from a tab base (15A) to a tab tip (15B) which is narrower than the tab base, and each slot is defined by two opposed, short, end faces (26) and two opposed, elongate "Z side faces, said side faces comprising opposed center parts (27), each at least as long as the width of the tab tip, and opposed flanking parts (28) on either side of the center parts extending from the center parts to the respective end faces.